Lauren Tweel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lauren Tweel has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Charlene Compher
Biobehavioral Health Science Department and Nutrition Programs, University of Pennsylvania School of Nursing, Philadelphia, PA, USA
2 shared publications - Daren K. Heyland
Kingston General Hospital Clinical Evaluation Research Unit Kingston Ontario Canada
2 shared publications Andrew G. Day
Kingston Health Science Centre Research Institute Kingston Ontario Canada
1 shared publication- Andrew G. Day
Kingston Health Sciences Centre Research Institute, Kingston, ON, Canada
1 shared publication - Angela Parillo
The Ohio State University Wexner Medical Center, Department of Clinical Nutrition, Columbus, Ohio, USA
1 shared publication Anna Howard
1 shared publication
Latest Publications
- Open Access
- 7 November 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 144, 20-34
Ketogenic diet therapy in adults with status epilepticus: A systematic review
- 7 November 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 144, 20-34
Open AccessKetogenic diet therapy in adults with status epilepticus: A systematic review
- Open Access
- 14 November 2025
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 50 (2) , 183-191
Association between protein dose in the early and late acute phases of critical illness and time‐to‐discharge‐alive: A secondary analysis of a randomized clinical trial
Background: Research has sought to identify optimal protein doses during acute phases of critical illness to optimize outcomes. Methods: A secondary analysis of the EFFORT Protein trial, which compared high vs usual protein ( N = 1301). Only participants with 8 evaluable days of protein intake were included in our analysis. Mean protein intake was categorized as low (1.3 g/kg/day). Acute illness phases were define as early (days 1–4) and late (days 5–8). Participants were grouped by protein dose received in each phase. Based on prior evidence, early phase medium protein/late phase high protein served as the referent. The primary outcome was time‐to‐discharge‐alive; secondary outcomes included 60‐day mortality and discharge home. Results: We identified 819 participants (median [IQR] age 59.0 [46.0, 69.0] years; 60% male). Time‐to‐discharge‐alive did not differ significantly across groups ( P = 0.19). The early low/late high‐protein and early high/late high‐protein groups had hazard ratios of 0.63 (95% CI, 0.35–1.11) and 0.70 (95% CI, 0.46–1.06), respectively. Mortality and discharge‐home rates did not differ significantly across protein dose/acute phase groups ( P = 0.85 and 0.65, respectively). Conclusion: We hypothesized that early medium and late high protein would improve outcomes; however, no significant differences between were observed across protein dose/acute phase groups. These findings are hypothesis‐generating and highlight the need for future research to identify biomarkers or scoring tools that better define phase transitions in critical illness, enabling more precise nutrition strategies. Trial Registration (Primary): NCT03160547
- 14 November 2025
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 50 (2) , 183-191
Open AccessAssociation between protein dose in the early and late acute phases of critical illness and time‐to‐discharge‐alive: A secondary analysis of a randomized clinical trial
Background: Research has sought to identify optimal protein doses during acute phases of critical illness to optimize outcomes. Methods: A secondary analysis of the EFFORT Protein trial, which compared high vs usual protein ( N = 1301). Only participants with 8 evaluable days of protein intake were included in our analysis. Mean protein intake was categorized as low (1.3 g/kg/day). Acute illness phases were define as early (days 1–4) and late (days 5–8). Participants were grouped by protein dose received in each phase. Based on prior evidence, early phase medium protein/late phase high protein served as the referent. The primary outcome was time‐to‐discharge‐alive; secondary outcomes included 60‐day mortality and discharge home. Results: We identified 819 participants (median [IQR] age 59.0 [46.0, 69.0] years; 60% male). Time‐to‐discharge‐alive did not differ significantly across groups ( P = 0.19). The early low/late high‐protein and early high/late high‐protein groups had hazard ratios of 0.63 (95% CI, 0.35–1.11) and 0.70 (95% CI, 0.46–1.06), respectively. Mortality and discharge‐home rates did not differ significantly across protein dose/acute phase groups ( P = 0.85 and 0.65, respectively). Conclusion: We hypothesized that early medium and late high protein would improve outcomes; however, no significant differences between were observed across protein dose/acute phase groups. These findings are hypothesis‐generating and highlight the need for future research to identify biomarkers or scoring tools that better define phase transitions in critical illness, enabling more precise nutrition strategies. Trial Registration (Primary): NCT03160547